Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
SMMT enters its October 20 earnings date with an unusual combination: a management team that bought heavily at lower prices, short sellers who have been quietly rebuilding positions, and analyst targets spread across a range too wide to be useful as consensus.
The short interest story is the clearest place to start. Shorts have been adding steadily. Short interest as a percentage of the free float has climbed to 5.3%, up 4.1% on the week and 8.6% over the past month, the highest level since mid-September. That gradual rebuild follows a dip in early September when SI fell from the low 40 million share range to near 37 million. The reversal since then has been consistent. Borrow costs remain low at under 1%, down roughly 21% on the week, so this is not an expensive trade for bears. Availability has tightened notably, dropping 31% week on week to about 104% of outstanding short interest, compared with readings above 150% through most of September. That tightening is worth watching: it suggests demand for borrows is rising faster than supply is being released. On options, the put/call ratio is running at 0.68, barely half a standard deviation above its 20-day average of 0.66. Options traders are not particularly defensive. That diverges from the short interest direction, which is the genuine tension in this week's setup.
The Street is split in a way that reflects deep uncertainty about the clinical story. The most recent meaningful move came from Jefferies in early September, upgrading to Buy with a target of $25. Barclays raised its target to $20 this week while keeping an Equal-Weight rating. Citigroup is at the other extreme, lifting to $43 on a Buy. The mean target at $22.50 sits roughly 30% above the current price of $17.31, but that average conceals a huge dispersion. The bull case centres on Summit's oncology pipeline and near-term data catalysts. The bear case focuses on whether early efficacy signals for ivonescimab hold up in larger trials, with bears noting the small shift in PFS hazard ratios and the absence of updated PD-L1 subgroup data. Factor scores add nuance: the analyst recommendation differential ranks in the 92nd percentile, meaning the relative shift in analyst positioning has been unusually bullish compared with the broader universe. Short score ranks in just the 7th percentile, which is low.
Retail attention is running unusually high. The ORTEX alt data layer shows a Wikipedia views signal at a z-score of 3.66 as of late September, well above the stock's own 90-day history. That is an attention signal, not a revenue indicator, but it captures a spike in retail interest that does not yet have an obvious fundamental anchor ahead of the October 20 print.
The ownership structure here is distinctive and worth naming explicitly. Co-CEOs Robert Duggan and Mahkam Zanganeh together hold close to 77% of shares outstanding. In June, both made open-market purchases totalling 3.81 million shares each at $13.12, discretionary buys not made under a 10b5-1 plan, with the stock now trading at $17.31. The CFO also bought in early June. At that level of concentration, any meaningful change in insider positioning carries outsized information content. The most recent insider activity on record dates from June 12, so the 90-day net of roughly $103.6 million in open-market purchases reflects that June cluster rather than any fresh signal.
Prior earnings reactions provide limited comfort for positioning. The August 4 print produced a 3.7% gain on the day and a 15.9% five-day move. The late July event went the other way, with a 7.3% drop on the day and an 8.8% decline over five sessions. Both reactions were material. With the short score holding near 75.7, availability tightening into the print, and the stock up 5.6% on the week but still negative over a month, the setup into October 20 is one where the lending market and the options market are telling different stories, and one of them will be wrong.
See the live data behind this article on ORTEX.
Open SMMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
